Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...
Approximately one in seven couples face difficulties conceiving a child naturally. Half of these cases are due to male infertility—either caused by the complete absence or low number of mature sperm.
CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or ...
DUBLIN--(BUSINESS WIRE)--The "Global Molecular Diagnostics Market Report by Technology Application Product End Users Countries and Company Analysis 2024-2032" report has been added to ...
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...
Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.
Baylor Genetics, a joint venture clinical diagnostic laboratory at the forefront of genetic testing, and the Department of Molecular and Human Genetics at Baylor College of Medicine have entered a lab ...
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (MYGN) (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (SOPH) (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results